Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A Phase 2 trial of atacicept, a humanized recombinant protein that suppresses B cell function, demonstrated a negative impact on clinical disease activity in relapsing-remitting multiple sclerosis.

B-lymphocyte Targeted Therapies for MS — Paradoxical Effect of Atacicept